logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
Q

Qian Chu

tongji hospital of tongji medical college
H指数:53
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PancDS in Real-World Practice: A Prospective Multicenter Validation of a Clinical Decision-Support System Bridging Experience Gaps in Pancreatic Lesion Diagnosis

真实世界实践中的PancDS：一项前瞻性多中心临床决策支持系统的验证研究，以弥合胰腺病变诊断中的经验差距

Advanced Science
IF14.1
2026-05-190
OAAI
Zhibo Wang; Weinuo Qu; Wenwen Cai; Chuhuai Wang; Chenxi Lyu; Qingguo Xie; Qian Chu; Yaqi Shen; Peng Xiao; Feng Li; Qingpeng Zhang; Jiali Li; Jeong Min Lee; Zhen Li
Publisher Correction: SLC2A1+ tumour-associated macrophages spatially control CD8+ T cell function and drive resistance to immunotherapy in non-small-cell lung cancer

出版商更正: SLC2A1肿瘤相关巨噬细胞在空间上控制CD8 T细胞功能并驱动非小细胞肺癌对免疫疗法的抵抗

Nature Cell Biology
IF19.1
2026-01-190
OAAI
Lei Wang; Han Chu; Degao Chen; Yuxuan Wei; Jia Jia; Liqi Li; Linfeng He; Lina Peng; Fangfang Liu; Shanshan Huang; Zheng Jin; Dong Zhou; WenFeng Fang; Tao Jiang; Shouxia Xu; Xiaofang Ding; Haoyang Cai; Xindong Liu; Qingzhu Jia; Bo Zhu; Qian Chu
Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial

Glecirasib联合sitneprotafib在中国KRASG12C突变非小细胞肺癌患者中的疗效：一项开放标签、多中心、单臂、I/IIa期临床试验

The Lancet Respiratory Medicine
IF32.8
2025-11-290
PRE
Jia Zhong; Jun Zhao; Jianchun Duan; Jian Fang; Kailun Fei; Xiaoyan Li; Jiayan Chen; Zhijie Wang; Qian Chu; Yan Yu; Zhe Liu; Li Zhang; Yanqiu Zhao; Xingya Li; Lin Wu; Ligang Xing; Wu Zhuang; Xuefeng Fang; Jianhua Chang; Yueyin Pan
Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis

与健康相关的生活质量在间变性淋巴瘤激酶（ALK）阳性非小细胞肺癌（NSCLC）患者中使用第一代和下一代ALK酪氨酸激酶抑制剂（TKIs）治疗：一项系统评价和荟萃分析

Quality of Life Research
IF2.7
2025-11-280
OAAI
Yan Huang; Qian Chu; Jiejun Wang; Li Zhang
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial

Ivonescimab 联合化疗与 tislelizumab 联合化疗作为晚期鳞状非小细胞肺癌的一线治疗（HARMONi-6）：一项随机、双盲、Ⅲ期临床试验

The Lancet
IF97.3
2025-10-190
PRE
Zhiwei Chen; Fang Yang; Zhou Jiang; Longhua Sun; Lin Wu; Zhengxiang Han; Yun Fan; Yanqiu Zhao; Xingya Li; Haipeng Xu; Xiangjiao Meng; Ying Liu; Zhiye Zhang; Hui Luo; Xuelei Ma; Xuezhen Ma; Qin Shi; Zhongmin Zhang; Runxiang Yang; Pingli Wang; Pinhua Pan; Xiaohong Ai; Jie Li; Xingxiang Pu; Zhiwu Wang; Jian Fang; Ming He; Yong He; Shuliang Guo; Juan Li; Hongbiao Wang; Junqiang Zhang; Qian Chu; Xuewen Liu; Shenpeng Ying; Hongcheng Wu; Hongmei Sun; Yinghua Ji; Ming Zhou; Chao Cao; Kejing Tang; Zhengguo Li; Dairong Li; Zhihong Zhang; Jie Li; Jianya Zhou; Hongzhong Yang; Yingying Du; Hui Yang; Jian Shi; Hualin Chen; Wenting Li; Dongmei Lu; Mingxiu Hu; Zhongmin Maxwell Wang; Baiyong Li; Michelle Xia; Shun Lu

研究方向

暂未获取到该数据
K
Kongming Wu
H 指数:81论文数:340被引数:2.3万
易鸣 封面图
易鸣
H 指数:56论文数:188被引数:1.4万
X
Xun Yuan
H 指数:35论文数:114被引数:5,161
S
Shuang Qin
H 指数:28论文数:110被引数:5,445
Z
Zhen Li
H 指数:58论文数:1,286被引数:1.8万
L
Lin Wu
H 指数:59论文数:473被引数:1.7万
周
周清
H 指数:58论文数:532被引数:1.6万
Y
Yi‐Long Wu
H 指数:135论文数:2,242被引数:11.2万
张鹏 封面图
张鹏
H 指数:52论文数:384被引数:1.1万
G
Gen Lin
H 指数:20论文数:153被引数:1,497